Advanced age and liability to oxaliplatin-induced peripheral neuropathy: Post hoc analysis of a prospective study

European Journal of Neurology

Volumn 20, Issue 5, 2013, Pages 788-794

  Argyriou, A A ^a,b   Briani, C ^c   Cavaletti, G ^d   Bruna, J ^e   Alberti, P ^d   Velasco, R ^e   Lonardi, S ^f   Cortinovis, D ^b,g   Cazzaniga, M ^b,g   Campagnolo, M ^c   Santos, C ^e   Kalofonos, H P ^b  

^a UNIVERSITY GENERAL HOSPITAL OF PATRAS   (Greece)

^b UNIVERSITY HOSPITAL OF PATRAS   (Greece)

^c UNIVERSITY OF PADOVA   (Italy)

^d UNIVERSITY OF MILANO BICOCCA   (Italy)

^e HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^f VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^g SAN GERARDO HOSPITAL   (Italy)

Author keywords

Elderly; Incidence; Neuropathy; Neurotoxicity; Oxaliplatin; Severity

Indexed keywords

CAPECITABINE; FLUOROURACIL; OXALIPLATIN;

ADULT; AGED; ARTICLE; COLORECTAL CANCER; COMORBIDITY; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ELECTROPHYSIOLOGY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROPHYSIOLOGY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEURAL CONDUCTION; ORGANOPLATINUM COMPOUNDS; PERIPHERAL NERVOUS SYSTEM DISEASES; PROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 84876345168     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/ene.12061     Document Type: Article

References (29)

1. Howerton MW, Gibbons MC, Baffi CR, et al. Provider roles in the recruitment of underrepresented populations to cancer clinical trials. Cancer 2007; 109: 465-476.
2. Townsley CA, Selby R, Siu LL. Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials. J Clin Oncol 2005; 23: 3112-3124.
3. Potosky A, Harian LC, Kaplan RS, Johnson KA, Lynch CF. Age, sex, racial differences in the use of standard adjuvant therapy for colorectal cancer. J Clin Oncol 2002; 20: 1192-1202.
4. Meulenbeld HJ, Creemers GJ. First-line treatment strategies for elderly patients with metatstatic colorectal cancer. Drugs Aging 2007; 24: 223-238.
5. Goldberg RM, Tabah-Fisch I, Bleiberg H, et al. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol 2006; 24: 4085-4091.
6. Cho YH, Kim SY, Hong Lee M, et al. Comparative analysis of the efficacy and safety of chemotherapy with oxaliplatin plus fluorouracil/leucovorin between elderly patients over 65 years and younger patients with advanced gastric cancer. Gastric Cancer 2012; 15: 389-395.
7. Andre T, Boni C, Mounedji-Boudiaf L, et al. for the Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350: 2343-2351.
8. Kalofonos HP, Aravantinos G, Kosmidis P, et al. Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: a multicenter, randomized, phase II study. Ann Oncol 2005; 16: 869-877.
9. Rothenberg ML, Cox JV, Butts C, et al. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study. Ann Oncol 2008; 19: 1720-2726.
10. Argyriou AA, Bruna J, Marmiroli P, Cavaletti G. Chemotherapy-induced peripheral neurotoxicity (CIPN): an update. Crit Rev Oncol Hematol 2012; 82: 51-77.
11. Argyriou AA, Polychronopoulos P, Iconomou G, et al. Incidence and characteristics of peripheral neuropathy during oxaliplatin-based chemotherapy for metastatic colon cancer. Acta Oncol 2007; 46: 1131-1137.
12. Argyriou AA, Polychronopoulos P, Iconomou G, Chroni E, Kalofonos HP. A review on oxaliplatin-induced peripheral nerve damage. Cancer Treat Rev 2008; 34: 368-377.
13. Baek KK, Lee J, Park SH, et al. Oxaliplatin-induced chronic peripheral neurotoxicity: a prospective analysis in patients with colorectal cancer. Cancer Res Treat 2010; 42: 185-190.
14. Argyriou AA, Polychronopoulos P, Koutras A, et al. Is advanced age associated with increased incidence and severity of chemotherapy-induced peripheral neuropathy? Support Care Cancer 2006; 14: 223-239.
15. Argyriou AA, Zolota V, Kyriakopoulou O, Kalofonos HP. Toxic peripheral neuropathy associated with commonly used chemotherapeutic agents. J BUON 2010; 15: 435-446.
16. National Cancer Institute. Common Toxicity Criteria version 3.0. (CTCAE v3.0), 2003. Available at: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf (accessed 25/06/2012).
17. Cavaletti G, Frigeni B, Lanzani F, et al. The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale. J Peripher Nerv Syst 2007; 12: 210-215.
18. Cavaletti G, Frigeni B, Lanzani F, et al. Chemotherapy-Induced peripheral neurotoxicity assessment: a critical revision of the currently available tools. Eur J Cancer 2010; 46: 479-494.
19. Antonacopoulou AG, Argyriou AA, Scopa CD, et al. Integrin beta-3 L33P: a new insight into the pathogenesis of chronic oxaliplatin-induced peripheral neuropathy? Eur J Neurol 2010; 17: 963-968.
20. Argyriou AA, Velasco R, Briani C, et al. Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients. Ann Oncol 2012; 23: 3116-3122.
21. Kimura J. Electrodiagnosis in Diseases of Nerve and Muscle, Principles and Practice (edn 3). New York, USA: Oxford University Press, 2001: 91-166.
22. Wedding U, Honecker F, Bokemeyer C, Pientka L, Höffken K. Tolerance to chemotherapy in elderly patients with cancer. Cancer Control 2007; 14: 44-56.
23. Quinn MJ, d'Onofrio A, Møller B, et al. Cancer mortality trends in the EU and acceding countries up to 2015. Ann Oncol 2003; 14: 1148-1152.
24. Hotta K, Ueoka H, Kiura K, Tabata M, Tanimoto M. An overview of 48 elderly-specific clinical trials of systemic chemotherapy for advanced non-small cell lung cancer. Lung Cancer 2004; 46: 61-76.
25. Verdu E, Ceballos D, Vilches JJ, Navarro X. Influence of aging on peripheral nerve function and regeneration. J Peripher Nerv Syst 2000; 5: 191-208.
26. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. Chapter: Competing Risk and Multistate Models, 2nd edn. New Jersey: John Wiley, 2002: 248-265.
27. Figer A, Perez-Staub N, Carola E, et al. FOLFOX in patients aged between 76 and 80 years with metastatic colorectal cancer: an exploratory cohort of the OPTIMOX1 study. Cancer 2007; 110: 2666-2671.
28. Sastre J, Aranda E, Massutí B, et al. Elderly patients with advanced colorectal cancer derive similar benefit without excessive toxicity after first-line chemotherapy with oxaliplatin-based combinations: comparative outcomes from the 03-TTD-01 phase III study. Crit Rev Oncol Hematol 2009; 70: 134-144.
29. Benavides M, Pericay C, Valladares-Ayerbes M, et al. Oxaliplatin in combination eith infusional 5-fluorouracil as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a Phase II study of the Spanish Cooperative Group for the treatment of digestive tumors. Clin Colorectal Cancer 2012; 11: 200-206.